Fulcrum Therapeutics (FULC) Preferred Stock Liabilities (2018 - 2019)

Fulcrum Therapeutics' (FULC) quarterly Preferred Stock Liabilities came in at $59.9 million in Q2 2019, little changed year-on-year from $59.9 million in Q2 2018, and little changed on a QoQ basis from $59.9 million in Q1 2019.

Fulcrum Therapeutics (FULC) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

Fulcrum Therapeutics (FULC) has 2 years of Preferred Stock Liabilities data on file, last reported at $59.9 million in Q2 2019.

  • On a quarterly basis, Preferred Stock Liabilities changed 0.0% year-over-year to $59.9 million in Q2 2019; TTM through Jun 2019 was $59.9 million, a 0.0% change from a year earlier, with the FY2018 full-year figure at $79.8 million, changed N/A from the prior year.
  • Preferred Stock Liabilities for Q2 2019 stood at $59.9 million, roughly flat from $59.9 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for FULC reached as high as $79.8 million in Q4 2018 and fell as low as $59.9 million in Q2 2018.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Fulcrum Therapeutics 286.57 Mn 286.57 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2019 59.91 Mn
Mar 31, 2019 59.91 Mn
Dec 31, 2018 79.76 Mn
Sep 30, 2018 59.91 Mn
Jun 30, 2018 59.91 Mn